TY - JOUR
T1 - Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease
AU - Schofield, Christine
AU - Chaudhuri, K. Ray
AU - Carroll, Camille
AU - Sharma, Jagdish C.
AU - Pavese, Nicola
AU - Evans, Jonathan
AU - Foltynie, Thomas
AU - Reichmann, Heinz
AU - Zurowska, Laura
AU - Soares-Da-Silva, Patrício
AU - Lees, Andrew
PY - 2022/4
Y1 - 2022/4
N2 - Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.
AB - Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1298/viewcontent/nmt_2021_0057.pdf
U2 - 10.2217/nmt-2021-0057
DO - 10.2217/nmt-2021-0057
M3 - Article
SN - 1758-2024
VL - 12
SP - 77
EP - 91
JO - Neurodegenerative Disease Management
JF - Neurodegenerative Disease Management
IS - 2
ER -